Covaxin has been found to be effective against the B.1.617 and B.1.1.7 variants of COVID-19 which were first identified in India and the UK.
Bharat Biotech, the manufacturer of Covaxin, informed on Sunday that their vaccine has produced neutralising titres (concentration) against all key emerging variants.
The Hyderabad-based company conducted a study in collaboration with National Institute of Virology – India Council of Medical Research. It found a modest reduction in neutralisation by a factor of 1.95 was observed against the B.1.617 variant compared to the vaccine variant (D614G). Despite this reduction, though, neutralizing titre levels with B.1.617 remained above levels expected to be protective.
Also Read: Covaxin Trial For Children Cleared In India
“No difference in neutralization between B.1.1.7 (first found in the UK) and vaccine strain (D614G) was observed,” Bharat Biotech added.
Covaxin and Covishield are being used in India’s vaccination process which started in mid-January, with Russian vaccine Sputnik V being the latest entrant.
Bhubaneswar: The Indian Navy will showcase its maritime strength with an operational demonstration at Blue…
New Delhi K Sanjay Murthy, a 1989-batch Himachal Pradesh cadre IAS officer, will be India's…
New Delhi: In a move that marks a major change in policy for Washington, US…
New Delhi: The Supreme Court bench hearing petitions linked to Delhi's toxic air quality was…
Bhubaneswar: The state government has extended the last date for submission of inputs for preparation…
Bhubaneswar: The Forest Department has suspended three field officials in connection with the electrocution death…
Mumbai: The first poster of the Tiger Shroff-starrer ‘Baaghi 4’ is out. The poster shows…
Bhubaneswar: What came first -- chicken or egg? Scientists have finally found some evidence to…